Contrasting iCAD (NASDAQ:ICAD) and Haemonetics (NYSE:HAE)

Haemonetics (NYSE:HAE) and iCAD (NASDAQ:ICAD) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends and earnings.

Analyst Recommendations

This is a summary of recent recommendations for Haemonetics and iCAD, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Haemonetics	1	1	6	1	2.78
iCAD	0	3	0	0	2.00

Haemonetics presently has a consensus price target of $97.89, indicating a potential upside of 42.34%. Given Haemonetics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Haemonetics is more favorable than iCAD.

Institutional and Insider Ownership

99.7% of Haemonetics shares are held by institutional investors. Comparatively, 24.6% of iCAD shares are held by institutional investors. 1.8% of Haemonetics shares are held by insiders. Comparatively, 10.3% of iCAD shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Haemonetics and iCAD”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Haemonetics	$1.36 billion	2.54	$117.56 million	$3.31	20.78
iCAD	$19.61 million	5.32	-$4.85 million	($0.21)	-18.10

Haemonetics has higher revenue and earnings than iCAD. iCAD is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Haemonetics has a beta of 0.32, suggesting that its share price is 68% less volatile than the S&P 500. Comparatively, iCAD has a beta of 1.35, suggesting that its share price is 35% more volatile than the S&P 500.

Profitability

This table compares Haemonetics and iCAD’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Haemonetics	9.47%	23.66%	8.82%
iCAD	-17.81%	-15.65%	-12.52%

Summary

Haemonetics beats iCAD on 12 of the 15 factors compared between the two stocks.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

About iCAD

iCAD, Inc. engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.